GSK welcomes external scientists to diseases of the developing world research campus

GSK will provide support, expertise and facilities as part of our open innovation strategy to spur global collaboration in research

Issued:London UK

GSK will provide support, expertise and facilities as part of our open innovation strategy to spur global collaboration in research

External researchers from six medical research organisations have begun work in the GlaxoSmithKline (GSK) ‘open lab’ in Spain, as part of GSK’s experiment to stimulate collaboration in the search for new medicines against diseases of the developing world, such as malaria and drug resistant tuberculosis.

In total, eight scientists from six organisations from four countries, including the United States and South Africa will work on their own research projects in association with GSK scientists at the Tres Cantos research campus. They are the first external researchers to take up the ‘open lab’ placements since GSK announced that it was seeking to be more collaborative in this area of research.

In 2010, GSK stated its intention to open its research campus outside of Madrid, Spain to allow GSK researchers to work more collaboratively with scientists from universities, not-for-profit partnerships and other research institutes with the aim of discovering and developing new medicines for diseases of the developing world. The facility has made capacity for independent researchers to work alongside approximately 120 GSK scientists, accessing the state of the art facilities and expertise.

“The challenge of improving healthcare in the developing world is enormous and far too complex to be addressed by any one group or organisation alone. Success will require creative thinking and the identification of new ways for industry, academia, NGOs and governments to work together,” said Nick Cammack, Senior Vice President and head of the Tres Cantos Medicines Development Campus. “We are fully committed to playing our part and the initiation of these research projects at Tres Cantos represents an exciting step forward in a new, more open approach to stimulate research into new medicines for deadly diseases that affect the developing world.”

Half of this first wave of research projects are being supported by the Tres Cantos Open Lab Foundation, a non-profit group established with a £5m ($8m) donation in seed-funding from GSK to support suitable research projects.

Among the projects underway are research to identify and optimise compounds that could be tested in humans against multi-drug resistant TB, three separate projects into malaria, including one that investigates potential compounds from the GSK chemical library, and a new approach against the parasites that can cause leishmaniasis.

"This is an innovative model for research collaboration, with the potential for transformative outcomes for medicine in the developing world,” said Professor Sir Leszek Borysiewicz, Trustee and Chair of the Governing Board, Tres Cantos Open Lab Foundation and current Vice-Chancellor of the University of Cambridge.

About the Projects

CRESIB, Spain (The Barcelona Centre for International Health Research): A two-year project to create a continuous lab-based supply of the P. vivax malaria parasite in the blood stage. If successful this project will offer a technology breakthrough that could allow further advances in research on P. Vivax.

About Tres Cantos Open Lab Foundation

The Tres Cantos Open Lab Foundation is focussed on providing funding and support for scientists, academics and institutions to develop and advance new ideas that could lead to new medicines to treat diseases of the developing world. Researchers are invited to submit projects for collaboration and funding, to be reviewed by the Foundation’s Governing Board and Trustees. www.openlabfoundation.org

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline enquiries:

UK Media enquiries:

David Mawdsley

(020) 8047 5502

Stephen Rea

(020) 8047 5502

Alexandra Harrison

(020) 8047 5502

Janet Morgan

(020) 8047 5502

David Daley

(020) 8047 5502

US Media enquiries:

Nancy Pekarek

(919) 483 2839

Mary Anne Rhyne

(919) 483 2839

Kevin Colgan

(919) 483 2839

Jennifer Armstrong

(919) 483 2839

European Analyst/Investor enquiries:

Sally Ferguson

(020) 8047 5543

Gary Davies

(020) 8047 5503

Ziba Shamsi

(020) 8047 3289

US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419

Jeff McLaughlin

(215) 751 7002

GlaxoSmithKline cautionary statement regarding forward-looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.